Renata PLC has initiated its first shipment of Risperidone, a key medication for managing psychiatric disorders, to the United States. Manufactured at its FDA-approved facility in Bangladesh, the consignment includes 12 million tablets in lower dosages of 0.25 mg, 0.5 mg, and 1 mg stated in a report.
The company is also in the process of obtaining approval for higher doses, including 2 mg, 3 mg, and 4 mg, to offer patients greater flexibility in managing conditions like schizophrenia, bipolar disorder, and autism-related irritability.
Read more: Bangladesh’s Economic Growth Under Scrutiny As FY24 GDP Estimated At $300 Billion
This shipment expands Renata’s portfolio in the US market, marking a significant milestone as the company ventures into the segment of neurological disorders. By targeting this area, Renata aims to address a critical need in the US healthcare system while strengthening its global footprint in the pharmaceutical industry.
For more updates, be with Markedium.
